Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba
G
G
Department of Dermatology, Nishtar Medical College/Hospital, Multan, Pakistan.
Khalid
M
M
D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage*; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate